Japan's PAFSC gives nods to Takeda's glatiramer, MSD's omarigliptin

Japan's Pharmaceutical Affairs and Food Sanitation Council's First Committee on Drugs, or PAFSC, gave the go ahead to Takeda Pharmaceutical's glatiramer acetate application last week, a spokesman for the Ministry of Health, Labor and Welfare said. In addition, PAFSC, a review committee that effectively approves drugs for marketing, endorsed Merck Sharp & Dohme's ($MRK) DPP-4 inhibitor omarigliptin, and a fixed-dose combination of DPP-4 inhibitor Equa and biguanide metformin from  Novartis ($NVS). The omarigliptin approval enters a crowded field in Japan. As well, a pediatric dose of Tracleer from Actelion Pharmaceuticals ($ATLN) was approved along with Bayer's iloprost. Also in the docket, PAFSC said that GlaxoSmithKline's ($GSK) dutasteride for androgenetic alopecia in men. MHLW website